US2056046A
(en)
|
1933-05-19 |
1936-09-29 |
Rhone Poulenc Sa |
Manufacture of bases derived from benz-dioxane
|
US2375138A
(en)
|
1942-05-01 |
1945-05-01 |
American Cyanamid Co |
Alkamine esters of aryloxymethyl benzoic acid
|
US2629736A
(en)
|
1951-02-24 |
1953-02-24 |
Searle & Co |
Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
|
US2730544A
(en)
|
1952-07-23 |
1956-01-10 |
Sahyun Lab |
Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
|
US2750387A
(en)
|
1953-11-25 |
1956-06-12 |
Searle & Co |
Basically substituted derivatives of diarylaminobenzamides
|
DE1211359B
(de)
|
1955-11-29 |
1966-02-24 |
Oreal |
Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
|
US2928833A
(en)
|
1959-03-03 |
1960-03-15 |
S E Massengill Company |
Theophylline derivatives
|
US3174901A
(en)
*
|
1963-01-31 |
1965-03-23 |
Jan Marcel Didier Aron Samuel |
Process for the oral treatment of diabetes
|
US3454635A
(en)
*
|
1965-07-27 |
1969-07-08 |
Hoechst Ag |
Benzenesulfonyl-ureas and process for their manufacture
|
DE1914999A1
(de)
|
1968-04-04 |
1969-11-06 |
Ciba Geigy |
Neue Guanylhydrazone und Verfahren zu ihrer Herstellung
|
ES385302A1
(es)
|
1970-10-22 |
1973-04-16 |
Miquel S A Lab |
Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina.
|
DE2205815A1
(de)
|
1972-02-08 |
1973-08-16 |
Hoechst Ag |
Piperazinderivate und verfahren zu ihrer herstellung
|
JPS5512435B2
(pt)
|
1972-07-01 |
1980-04-02 |
|
|
US4005208A
(en)
|
1975-05-16 |
1977-01-25 |
Smithkline Corporation |
N-Heterocyclic-9-xanthenylamines
|
US4061753A
(en)
|
1976-02-06 |
1977-12-06 |
Interx Research Corporation |
Treating psoriasis with transient pro-drug forms of xanthine derivatives
|
AU508480B2
(en)
|
1977-04-13 |
1980-03-20 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
|
DE2758025A1
(de)
|
1977-12-24 |
1979-07-12 |
Bayer Ag |
Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
|
NO154918C
(no)
|
1977-08-27 |
1987-01-14 |
Bayer Ag |
Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
|
DE2904885A1
(de)
|
1979-02-09 |
1980-08-14 |
Rothenberger Gmbh Co |
Biegevorrichtung fuer metallrohre
|
DE2929596A1
(de)
|
1979-07-21 |
1981-02-05 |
Hoechst Ag |
Verfahren zur herstellung von oxoalkyl-xanthinen
|
GB2084580B
(en)
|
1980-10-01 |
1984-07-04 |
Glaxo Group Ltd |
Aminoalkyl furan derivative
|
US4382091A
(en)
|
1981-04-30 |
1983-05-03 |
Syntex (U.S.A.) Inc. |
Stabilization of 1-substituted imidazole derivatives in talc
|
FR2558162B1
(fr)
|
1984-01-17 |
1986-04-25 |
Adir |
Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
|
FI79107C
(fi)
|
1984-06-25 |
1989-11-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
|
JPS6130567A
(ja)
|
1984-07-23 |
1986-02-12 |
Shiseido Co Ltd |
尿素の安定化法
|
JPS61124383A
(ja)
|
1984-11-16 |
1986-06-12 |
Unitika Ltd |
固定化線維素溶解活性酵素の安定化法
|
AR240698A1
(es)
*
|
1985-01-19 |
1990-09-28 |
Takeda Chemical Industries Ltd |
Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
|
CA1242699A
(en)
|
1985-02-01 |
1988-10-04 |
Bristol-Myers Company |
Cefbuperazone and derivatives thereof
|
US4741898A
(en)
|
1985-04-01 |
1988-05-03 |
Fisher Scientific Company |
Stabilized stain composition
|
GB8515934D0
(en)
|
1985-06-24 |
1985-07-24 |
Janssen Pharmaceutica Nv |
(4-piperidinomethyl and-hetero)purines
|
US5258380A
(en)
|
1985-06-24 |
1993-11-02 |
Janssen Pharmaceutica N.V. |
(4-piperidinylmethyl and -hetero)purines
|
ES2058061T3
(es)
|
1985-10-25 |
1994-11-01 |
Beecham Group Plc |
Derivado de piperidina, su preparacion y su uso como medicamento.
|
US5034225A
(en)
|
1985-12-17 |
1991-07-23 |
Genentech Inc. |
Stabilized human tissue plasminogen activator compositions
|
US5433959A
(en)
|
1986-02-13 |
1995-07-18 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
EP0237608B1
(de)
|
1986-03-21 |
1992-01-29 |
HEUMANN PHARMA GMBH & CO |
Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
DE3750402T3
(de)
|
1986-05-05 |
1997-04-10 |
Gen Hospital Corp |
Insulinotropes hormon.
|
AU619444B2
(en)
|
1986-06-02 |
1992-01-30 |
Nippon Chemiphar Co. Ltd. |
2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
|
US4968672A
(en)
|
1987-01-02 |
1990-11-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adenosine receptor prodrugs
|
US4743450A
(en)
|
1987-02-24 |
1988-05-10 |
Warner-Lambert Company |
Stabilized compositions
|
US5093330A
(en)
|
1987-06-15 |
1992-03-03 |
Ciba-Geigy Corporation |
Staurosporine derivatives substituted at methylamino nitrogen
|
JPS6440433A
(en)
|
1987-08-05 |
1989-02-10 |
Green Cross Corp |
Aqueous liquid composition of thrombin
|
DE68920773T2
(de)
|
1988-05-19 |
1995-05-18 |
Chugai Pharmaceutical Co Ltd |
Chinoloncarbonsäure-Derivate.
|
US5329025A
(en)
|
1988-09-21 |
1994-07-12 |
G. D. Searle & Co. |
3-azido compound
|
US5234897A
(en)
|
1989-03-15 |
1993-08-10 |
Bayer Aktiengesellschaft |
Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
|
DE3926119A1
(de)
|
1989-08-08 |
1991-02-14 |
Bayer Ag |
3-amino-5-aminocarbonyl-1,2,4-triazol-derivate
|
GB8906792D0
(en)
|
1989-03-23 |
1989-05-10 |
Beecham Wuelfing Gmbh & Co Kg |
Treatment and compounds
|
DE3916430A1
(de)
|
1989-05-20 |
1990-11-22 |
Bayer Ag |
Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten
|
US5223499A
(en)
|
1989-05-30 |
1993-06-29 |
Merck & Co., Inc. |
6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
|
IL94390A
(en)
|
1989-05-30 |
1996-03-31 |
Merck & Co Inc |
The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
|
US5332744A
(en)
|
1989-05-30 |
1994-07-26 |
Merck & Co., Inc. |
Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
HU208115B
(en)
*
|
1989-10-03 |
1993-08-30 |
Biochemie Gmbh |
New process for producting pleuromutilin derivatives
|
FR2654935B1
(fr)
|
1989-11-28 |
1994-07-01 |
Lvmh Rech |
Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
DE122007000050I1
(de)
|
1990-02-19 |
2007-11-08 |
Novartis Ag |
Acylverbindungen
|
KR930000861B1
(ko)
|
1990-02-27 |
1993-02-08 |
한미약품공업 주식회사 |
오메프라졸 직장투여 조성물
|
DE69104453T2
(de)
|
1990-09-13 |
1995-03-16 |
Akzo Nv |
Stabilisierte feste chemische Zusammensetzungen.
|
GB9020959D0
(en)
|
1990-09-26 |
1990-11-07 |
Beecham Group Plc |
Novel compounds
|
US5084460A
(en)
|
1990-12-24 |
1992-01-28 |
A. H. Robins Company, Incorporated |
Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
|
US5591762A
(en)
*
|
1991-02-06 |
1997-01-07 |
Dr. Karl Thomae Gmbh |
Benzimidazoles useful as angiotensin-11 antagonists
|
US5602127A
(en)
|
1991-02-06 |
1997-02-11 |
Karl Thomae Gmbh |
(Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
|
US5594003A
(en)
*
|
1991-02-06 |
1997-01-14 |
Dr. Karl Thomae Gmbh |
Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
|
GB9109862D0
(en)
|
1991-05-08 |
1991-07-03 |
Beecham Lab Sa |
Pharmaceutical formulations
|
DE4124150A1
(de)
|
1991-07-20 |
1993-01-21 |
Bayer Ag |
Substituierte triazole
|
TW225528B
(pt)
|
1992-04-03 |
1994-06-21 |
Ciba Geigy Ag |
|
US5300298A
(en)
|
1992-05-06 |
1994-04-05 |
The Pennsylvania Research Corporation |
Methods of treating obesity with purine related compounds
|
GB9215633D0
(en)
|
1992-07-23 |
1992-09-09 |
Smithkline Beecham Plc |
Novel treatment
|
ATE165360T1
(de)
|
1992-07-31 |
1998-05-15 |
Shionogi & Co |
Triazolylthiomethylthiocephalosporin- hydrochlorid, sein kristallines hydrat und seine herstellung
|
TW252044B
(pt)
|
1992-08-10 |
1995-07-21 |
Boehringer Ingelheim Kg |
|
US5358941A
(en)
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
DE4242459A1
(de)
|
1992-12-16 |
1994-06-23 |
Merck Patent Gmbh |
Imidazopyridine
|
WO1994015605A1
(en)
|
1993-01-14 |
1994-07-21 |
Cell Therapeutics, Inc. |
Acetal or ketal substituted therapeutic compounds
|
CA2118117A1
(en)
|
1993-02-18 |
1994-08-19 |
Shigeki Fujiwara |
Adenosine uptake inhibitor
|
JP3726291B2
(ja)
|
1993-07-05 |
2005-12-14 |
三菱ウェルファーマ株式会社 |
安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
|
FR2707641B1
(fr)
|
1993-07-16 |
1995-08-25 |
Fournier Ind & Sante |
Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
|
DE4339868A1
(de)
|
1993-11-23 |
1995-05-24 |
Merck Patent Gmbh |
Imidazopyridazine
|
DE4404183A1
(de)
|
1994-02-10 |
1995-08-17 |
Merck Patent Gmbh |
4-Amino-1-piperidylbenzoylguanidine
|
US5545745A
(en)
|
1994-05-23 |
1996-08-13 |
Sepracor, Inc. |
Enantioselective preparation of optically pure albuterol
|
CO4410190A1
(es)
|
1994-09-19 |
1997-01-09 |
Lilly Co Eli |
3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
|
EP0785927B1
(en)
|
1994-10-12 |
2003-08-27 |
Euroceltique S.A. |
Novel benzoxazoles
|
GB9501178D0
(en)
|
1995-01-20 |
1995-03-08 |
Wellcome Found |
Guanine derivative
|
US5821366A
(en)
|
1995-05-19 |
1998-10-13 |
Chiroscience Limited |
Xanthines and their therapeutic use
|
SK72096A3
(en)
|
1995-06-06 |
1997-11-05 |
Pfizer |
Indole-2-carboxamides, glycogen phosphorylase inhibitors and pharmauceutical compositions
|
WO1996039384A1
(en)
|
1995-06-06 |
1996-12-12 |
Pfizer, Inc. |
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
|
JPH08333339A
(ja)
|
1995-06-08 |
1996-12-17 |
Fujisawa Pharmaceut Co Ltd |
光学活性なピペリジン酢酸誘導体の製造法
|
GB9523752D0
(en)
|
1995-11-21 |
1996-01-24 |
Pfizer Ltd |
Pharmaceutical formulations
|
DE19543478A1
(de)
|
1995-11-22 |
1997-05-28 |
Bayer Ag |
Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
|
FR2742751B1
(fr)
|
1995-12-22 |
1998-01-30 |
Rhone Poulenc Rorer Sa |
Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
|
NZ326238A
(en)
|
1995-12-26 |
1999-11-29 |
Alteon Inc |
Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
|
US5891855A
(en)
|
1996-02-12 |
1999-04-06 |
The Scripps Research Institute |
Inhibitors of leaderless protein export
|
DE122010000020I1
(de)
|
1996-04-25 |
2010-07-08 |
Prosidion Ltd |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
TW518219B
(en)
|
1996-04-26 |
2003-01-21 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
AU1153097A
(en)
|
1996-06-07 |
1998-01-05 |
Eisai Co. Ltd. |
Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
|
US5965555A
(en)
|
1996-06-07 |
1999-10-12 |
Hoechst Aktiengesellschaft |
Xanthine compounds having terminally animated alkynol side chains
|
US5958951A
(en)
|
1996-06-14 |
1999-09-28 |
Novo Nordiskials |
Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
|
US5753635A
(en)
|
1996-08-16 |
1998-05-19 |
Berlex Laboratories, Inc. |
Purine derivatives and their use as anti-coagulants
|
CN1146567C
(zh)
|
1996-09-23 |
2004-04-21 |
伊莱利利公司 |
奥氮平二水合物d
|
AU4699697A
(en)
|
1996-10-28 |
1998-05-22 |
Novo Nordisk A/S |
A process for the preparation of (-)-3,4-trans-diarylchromans
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
ATE366584T1
(de)
|
1996-11-12 |
2007-08-15 |
Novo Nordisk As |
Verwendung von glp-1 peptiden
|
GB9623859D0
(en)
|
1996-11-15 |
1997-01-08 |
Chiroscience Ltd |
Novel compounds
|
NZ336548A
(en)
|
1996-12-24 |
2001-09-28 |
Biogen Inc |
Stable liquid interferon formulations comprising an amino acid as the stabilising agent
|
DE19705233A1
(de)
|
1997-02-12 |
1998-08-13 |
Froelich Juergen C |
Verfahren zur Herstellung einer Formulierung enthaltend Arginin
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6011049A
(en)
*
|
1997-02-19 |
2000-01-04 |
Warner-Lambert Company |
Combinations for diabetes
|
AU731186B2
(en)
|
1997-03-13 |
2001-03-29 |
Hexal Ag |
Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
|
US5972332A
(en)
|
1997-04-16 |
1999-10-26 |
The Regents Of The University Of Michigan |
Wound treatment with keratinocytes on a solid support enclosed in a porous material
|
AR012894A1
(es)
|
1997-06-13 |
2000-11-22 |
Lilly Co Eli |
Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
|
US6174548B1
(en)
|
1998-08-28 |
2001-01-16 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
SK8402000A3
(en)
|
1997-12-05 |
2001-03-12 |
Astrazeneca Uk Ltd |
Novel compounds
|
ID21411A
(id)
|
1997-12-10 |
1999-06-10 |
Takeda Chemical Industries Ltd |
Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
|
JPH11193270A
(ja)
|
1997-12-26 |
1999-07-21 |
Koei Chem Co Ltd |
光学活性1−メチル−3−ピペリジンメタノールの製造方法
|
AU1688599A
(en)
|
1998-01-05 |
1999-07-26 |
Eisai Co. Ltd. |
Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
|
CA2819705C
(en)
|
1998-02-02 |
2014-07-08 |
Trustees Of Tufts College |
Method of regulating glucose metabolism, and reagents related thereto
|
US5998463A
(en)
|
1998-02-27 |
1999-12-07 |
Pfizer Inc |
Glycogen phosphorylase inhibitors
|
US20030013740A1
(en)
|
1998-03-27 |
2003-01-16 |
Martin P. Redmon |
Stable dosage forms of fluoxetine and its enantiomers
|
JP2002509919A
(ja)
|
1998-03-31 |
2002-04-02 |
日産化学工業株式会社 |
ピリダジノン化合物塩酸塩及びその製造法
|
CA2268621A1
(en)
|
1998-04-13 |
1999-10-13 |
Takeda Chemical Industries, Ltd. |
2-pipirazinone-1-acetic acid derivative, production and use thereof
|
US6207207B1
(en)
|
1998-05-01 |
2001-03-27 |
Mars, Incorporated |
Coated confectionery having a crispy starch based center and method of preparation
|
DE19823831A1
(de)
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828114A1
(de)
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
CN1185013C
(zh)
|
1998-07-15 |
2005-01-19 |
旭化成株式会社 |
赋形剂
|
EP0978279A1
(en)
|
1998-08-07 |
2000-02-09 |
Pfizer Products Inc. |
Inhibitors of human glycogen phosphorylase
|
CO5150173A1
(es)
*
|
1998-12-10 |
2002-04-29 |
Novartis Ag |
Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
|
IT1312018B1
(it)
|
1999-03-19 |
2002-04-04 |
Fassi Aldo |
Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina.
|
SI1169312T1
(en)
|
1999-03-29 |
2005-02-28 |
F. Hoffmann-La Roche Ag |
Glucokinase activators
|
WO2000066101A2
(en)
|
1999-04-30 |
2000-11-09 |
City Of Hope |
Method of inhibiting glycation product formation
|
AU4431000A
(en)
|
1999-05-12 |
2000-12-05 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel use
|
US20040152659A1
(en)
|
1999-05-12 |
2004-08-05 |
Fujisawa Pharmaceutical Co. Ltd. |
Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
|
AU5294100A
(en)
|
1999-05-27 |
2000-12-18 |
University Of Virginia Patent Foundation |
Method and compositions for treating the inflammatory response
|
DE60034445T2
(de)
|
1999-05-31 |
2008-01-03 |
Mitsubishi Chemical Corp. |
Gefriergetrocknete hgf-präparationen
|
US6545002B1
(en)
|
1999-06-01 |
2003-04-08 |
University Of Virginia Patent Foundation |
Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
|
WO2000072973A1
(en)
|
1999-06-01 |
2000-12-07 |
Elan Pharma International Ltd. |
Small-scale mill and method thereof
|
EE04748B1
(et)
|
1999-06-21 |
2006-12-15 |
Boehringer Ingelheim Pharma Kg |
Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
|
US6448323B1
(en)
|
1999-07-09 |
2002-09-10 |
Bpsi Holdings, Inc. |
Film coatings and film coating compositions based on polyvinyl alcohol
|
ES2166270B1
(es)
|
1999-07-27 |
2003-04-01 |
Almirall Prodesfarma Sa |
Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
|
ES2216937T3
(es)
|
1999-08-31 |
2004-11-01 |
Kissei Pharmaceutical Co., Ltd. |
Derivados de glucopiranosiloxipirazol, composiciones medicinales que los contienen e intermedios obtenidos durante su preparacion.
|
EP1220832A1
(en)
|
1999-09-29 |
2002-07-10 |
Novo Nordisk A/S |
Novel aromatic compounds
|
EP1391460A1
(en)
|
1999-09-30 |
2004-02-25 |
Pfizer Products Inc. |
Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
|
PT1088824E
(pt)
|
1999-09-30 |
2004-04-30 |
Pfizer Prod Inc |
Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
|
PH12000002657B1
(en)
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
GB9928330D0
(en)
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
US6353111B1
(en)
|
1999-12-15 |
2002-03-05 |
Hoffmann-La Roche Inc. |
Trans olefinic glucokinase activators
|
AU777776B2
(en)
|
1999-12-23 |
2004-10-28 |
Novartis Ag |
Use of hypoglycemic agent for treating impaired glucose metabolism
|
CA2396079A1
(en)
|
2000-01-07 |
2001-07-19 |
Transform Pharmaceuticals, Inc. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
US6362172B2
(en)
|
2000-01-20 |
2002-03-26 |
Bristol-Myers Squibb Company |
Water soluble prodrugs of azole compounds
|
PT1741445E
(pt)
|
2000-01-21 |
2013-11-11 |
Novartis Ag |
Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
|
CO5271699A1
(es)
|
2000-01-24 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
|
JP4621326B2
(ja)
|
2000-02-01 |
2011-01-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
テプレノンの安定化組成物
|
WO2001056993A2
(en)
|
2000-02-05 |
2001-08-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of erk
|
EP1295609A4
(en)
|
2000-02-24 |
2004-11-03 |
Takeda Chemical Industries Ltd |
DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS
|
EP1132389A1
(en)
|
2000-03-06 |
2001-09-12 |
Vernalis Research Limited |
New aza-indolyl derivatives for the treatment of obesity
|
US6395767B2
(en)
*
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
GB0006133D0
(en)
|
2000-03-14 |
2000-05-03 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
MXPA02009034A
(es)
|
2000-03-17 |
2003-09-10 |
Kissei Pharmaceutical |
Derivados de glucopiranosiloxibencilbenceno, composiciones medicinales conteniendo los mismos e intermediarios para la preparacion de los derivados.
|
EP1136071A3
(en)
|
2000-03-22 |
2003-03-26 |
Pfizer Products Inc. |
Use of glycogen phosphorylase inhibitors
|
JP2001278812A
(ja)
|
2000-03-27 |
2001-10-10 |
Kyoto Pharmaceutical Industries Ltd |
錠剤用崩壊剤及びこれを用いた錠剤
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
US6683056B2
(en)
|
2000-03-30 |
2004-01-27 |
Bristol-Myers Squibb Company |
O-aryl glucoside SGLT2 inhibitors and method
|
US6555519B2
(en)
|
2000-03-30 |
2003-04-29 |
Bristol-Myers Squibb Company |
O-glucosylated benzamide SGLT2 inhibitors and method
|
EP1273306A4
(en)
|
2000-03-31 |
2005-06-22 |
Kirin Brewery |
POWDER PREPARATION INTENDED FOR MUCOUS MEMBRANES COMPRISING A POLYMERIC MEDICAMENT HAVING IMPROVED STORAGE STABILITY
|
CZ20023234A3
(cs)
|
2000-03-31 |
2003-01-15 |
Probiodrug Ag |
Léčivo proti diabetu
|
JP2001292388A
(ja)
|
2000-04-05 |
2001-10-19 |
Sharp Corp |
再生装置
|
GB0008694D0
(en)
|
2000-04-07 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
CN1209361C
(zh)
|
2000-05-03 |
2005-07-06 |
霍夫曼-拉罗奇有限公司 |
含乙内酰脲的葡糖激酶激活剂
|
US6388071B2
(en)
|
2000-05-03 |
2002-05-14 |
Hoffmann-La Roche Inc. |
Alkynyl phenyl heteroaromatic glucokinase activators
|
DE60134470D1
(de)
|
2000-05-08 |
2008-07-31 |
Hoffmann La Roche |
Para-amin substituierte phenylamid glukokinase activatoren
|
ES2230309T3
(es)
|
2000-05-08 |
2005-05-01 |
F. Hoffmann-La Roche Ag |
Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa.
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
ATE265424T1
(de)
|
2000-06-09 |
2004-05-15 |
Aventis Pharma Gmbh |
Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
US6962998B2
(en)
|
2000-06-14 |
2005-11-08 |
Toray Industries, Inc. |
Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
MXPA02012272A
(es)
|
2000-07-04 |
2003-04-25 |
Novo Nordisk As |
Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
|
EP1305301B1
(en)
|
2000-07-20 |
2005-06-15 |
F. Hoffmann-La Roche Ag |
Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
|
ATE411285T1
(de)
|
2000-08-10 |
2008-10-15 |
Mitsubishi Tanabe Pharma Corp |
Prolin-derivate und deren verwendung als medikamente
|
US6369232B1
(en)
|
2000-08-15 |
2002-04-09 |
Hoffmann-La Roche Inc. |
Tetrazolyl-phenyl acetamide glucokinase activators
|
GB0021831D0
(en)
|
2000-09-06 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
EP1329456B1
(en)
|
2000-09-29 |
2006-08-09 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
|
WO2002036602A1
(fr)
|
2000-11-02 |
2002-05-10 |
Ajinomoto Co., Inc. |
Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers
|
US20060034922A1
(en)
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US6722883B2
(en)
|
2000-11-13 |
2004-04-20 |
G & H Technologies Llc |
Protective coating for abrasive dental tools and burs
|
US7053060B2
(en)
|
2000-11-30 |
2006-05-30 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
|
JP4109111B2
(ja)
|
2000-12-06 |
2008-07-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
縮合複素環式芳香族グルコキナーゼアクチベーター
|
US6821261B2
(en)
|
2000-12-12 |
2004-11-23 |
Dj Orthopedics, Llc |
Orthopedic brace having length-adjustable supports
|
US6482951B2
(en)
|
2000-12-13 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Isoindolin-1-one glucokinase activators
|
EP1354882A1
(en)
|
2000-12-27 |
2003-10-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Dipeptidyl peptidase iv inhibitor
|
WO2002053573A1
(fr)
|
2000-12-28 |
2002-07-11 |
Kissei Pharmaceutical Co., Ltd. |
Derives de glucopyranosiloxypyrazole et leur utilisation dans des medicaments
|
FR2818906B1
(fr)
|
2000-12-29 |
2004-04-02 |
Dospharma |
Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
|
FR2819254B1
(fr)
|
2001-01-08 |
2003-04-18 |
Fournier Lab Sa |
Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
|
DE10109021A1
(de)
|
2001-02-24 |
2002-09-05 |
Boehringer Ingelheim Pharma |
Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
DE10117803A1
(de)
|
2001-04-10 |
2002-10-24 |
Boehringer Ingelheim Pharma |
Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
WO2002062764A1
(en)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Fused heterocyclic compounds
|
TWI255817B
(en)
|
2001-02-14 |
2006-06-01 |
Kissei Pharmaceutical |
Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
|
US6610326B2
(en)
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
US6649187B2
(en)
|
2001-02-16 |
2003-11-18 |
Bristol-Myers Squibb Pharma Company |
Use of polyalkylamine polymers in controlled release devices
|
ES2444772T3
(es)
|
2001-02-24 |
2014-02-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Derivados de xantina, su preparación y uso como medicamentos
|
CA2438593C
(en)
|
2001-02-26 |
2010-09-21 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivatives and medicinal use thereof
|
ES2350084T3
(es)
|
2001-02-27 |
2011-01-18 |
Kissei Pharmaceutical Co., Ltd. |
Derivados de glucopiranosiloxipirazol y uso médico de los mismos.
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6693094B2
(en)
*
|
2001-03-22 |
2004-02-17 |
Chrono Rx Llc |
Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
|
GB0107383D0
(en)
|
2001-03-23 |
2001-05-16 |
Univ Edinburgh |
Lipid profile modulation
|
US6774112B2
(en)
|
2001-04-11 |
2004-08-10 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
EP1389621A4
(en)
|
2001-04-27 |
2005-05-11 |
Ajinomoto Kk |
N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
|
JP2002348279A
(ja)
|
2001-05-25 |
2002-12-04 |
Nippon Kayaku Co Ltd |
光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体
|
PE20021091A1
(es)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
|
WO2002098893A1
(en)
|
2001-05-30 |
2002-12-12 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
|
CA2455300A1
(en)
|
2001-06-20 |
2003-01-03 |
Kissei Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
|
DE10130371A1
(de)
|
2001-06-23 |
2003-01-02 |
Boehringer Ingelheim Pharma |
Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
|
GB0115517D0
(en)
|
2001-06-25 |
2001-08-15 |
Ferring Bv |
Novel antidiabetic agents
|
US6901589B2
(en)
*
|
2001-06-25 |
2005-05-31 |
Wind River Systems, Inc. |
System and method for determining a root cause of a failure
|
SE0102299D0
(sv)
|
2001-06-26 |
2001-06-26 |
Astrazeneca Ab |
Compounds
|
SE0102300D0
(sv)
|
2001-06-26 |
2001-06-26 |
Astrazeneca Ab |
Compounds
|
JP4357293B2
(ja)
|
2001-06-27 |
2009-11-04 |
スミスクライン ビーチャム コーポレーション |
ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
|
BR0210644A
(pt)
|
2001-06-27 |
2004-07-20 |
Smithkline Beecham Corp |
Composto, formulação farmacêutica, método para inibir uma protease que cliva pós prolina/alanina, método para o tratamento ou profilaxia de distúrbios, e, uso do composto
|
JP4115105B2
(ja)
|
2001-07-02 |
2008-07-09 |
協和醗酵工業株式会社 |
ピラゾール誘導体
|
JP2005502624A
(ja)
|
2001-07-03 |
2005-01-27 |
ノボ ノルディスク アクティーゼルスカブ |
糖尿病を治療するための、dpp−ivを阻害するプリン誘導体
|
US6869947B2
(en)
|
2001-07-03 |
2005-03-22 |
Novo Nordisk A/S |
Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
MXPA04000224A
(es)
|
2001-07-10 |
2005-07-25 |
4Sc Ag |
Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
|
WO2003011880A1
(fr)
|
2001-07-31 |
2003-02-13 |
Kissei Pharmaceutical Co., Ltd. |
Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
AR035119A1
(es)
|
2001-08-16 |
2004-04-14 |
Lilly Co Eli |
Anticuerpos humanos antagonistas anti-htnfsf13b
|
SE0102764D0
(sv)
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
US20030087843A1
(en)
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
JPWO2003024942A1
(ja)
|
2001-09-14 |
2004-12-24 |
三菱ウェルファーマ株式会社 |
チアゾリジン誘導体およびその医薬用途
|
JP2005509603A
(ja)
|
2001-09-19 |
2005-04-14 |
ノボ ノルディスク アクティーゼルスカブ |
Dpp−iv酵素の阻害剤であるヘテロ環化合物
|
AU2002353784B2
(en)
|
2001-09-24 |
2008-04-10 |
Oregon Health And Science University |
Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
|
DK1435877T3
(da)
|
2001-10-15 |
2009-08-03 |
Hemoteq Ag |
Overtrækning af stents for at forhindre restenose
|
DE10151296A1
(de)
|
2001-10-17 |
2003-04-30 |
Boehringer Ingelheim Pharma |
Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
US20030083354A1
(en)
|
2001-10-26 |
2003-05-01 |
Pediamed Pharmaceuticals, Inc. |
Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
CA2465382A1
(en)
|
2001-10-29 |
2003-05-08 |
Japan Tobacco Inc. |
Indole compound and medicinal use thereof
|
CA2464995A1
(en)
*
|
2001-10-31 |
2003-05-08 |
Novartis Ag |
Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
|
CA2363053C
(en)
|
2001-11-09 |
2011-01-25 |
Bernard Charles Sherman |
Clopidogrel bisulfate tablet formulation
|
WO2003044000A1
(en)
|
2001-11-22 |
2003-05-30 |
Biovitrum Ab |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
PL370111A1
(en)
|
2001-11-22 |
2005-05-16 |
Biovitrum Ab |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
KR20050044517A
(ko)
|
2001-11-22 |
2005-05-12 |
바이오비트럼 에이비 |
11-베타-히드록시 스테로이드 탈수소효소 유형 1 의억제제
|
JP2005511636A
(ja)
|
2001-11-26 |
2005-04-28 |
トラスティーズ オブ タフツ カレッジ |
自己免疫疾患の治療方法及びそれに関する試薬
|
AU2002349299A1
(en)
|
2001-12-03 |
2003-06-17 |
Novo Nordisk A/S |
Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
|
KR20040064687A
(ko)
|
2001-12-21 |
2004-07-19 |
도오레 화인케미칼 가부시키가이샤 |
광학 활성 시스 피페리딘 유도체의 제조법
|
AU2002361861A1
(en)
|
2001-12-21 |
2003-07-30 |
Rhode Island Hospital |
SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
|
IL162620A0
(en)
|
2001-12-21 |
2005-11-20 |
Novo Nordisk As |
Amide derivatives as gk activators
|
US6727261B2
(en)
|
2001-12-27 |
2004-04-27 |
Hoffman-La Roche Inc. |
Pyrido[2,1-A]Isoquinoline derivatives
|
EP1466621A4
(en)
|
2001-12-28 |
2009-05-27 |
Nrl Pharma Inc |
COMPOSITIONS FOR ENHANCING LIPID METABOLISM
|
CA2472882A1
(en)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
|
US20070197552A1
(en)
|
2002-01-11 |
2007-08-23 |
Novo Nordisk A/S |
Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
|
DE60323823D1
(de)
|
2002-01-11 |
2008-11-13 |
Novo Nordisk As |
Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
|
CZ303145B6
(cs)
|
2002-01-16 |
2012-05-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Zpusob výroby dvojvrstevné farmaceutické tablety obsahující telmisartan a hydrochlorthiazid
|
CA2472205A1
(en)
|
2002-01-18 |
2003-07-24 |
Frank Robert Busch |
Intermediates for preparing glycogen phosphorylase inhibitors
|
CA2476984C
(en)
|
2002-01-21 |
2013-12-10 |
Nrl Pharma, Inc. |
Lactoferrin as an agent for enhancing action of an opioid
|
EP1333033A1
(en)
|
2002-01-30 |
2003-08-06 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
FAP-activated anti-tumor compounds
|
EP1469829B1
(en)
|
2002-02-01 |
2016-01-27 |
Bend Research, Inc |
Immediate release dosage forms containing solid drug dispersions
|
EP1474139B1
(en)
|
2002-02-01 |
2007-11-21 |
Merck & Co., Inc. |
11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
|
US7610153B2
(en)
|
2002-02-13 |
2009-10-27 |
Virginia Commonwealth University |
Multi-drug titration and evaluation
|
AU2003211146B2
(en)
|
2002-02-21 |
2007-07-19 |
Valeant International (Barbados) Srl |
Controlled release dosage forms
|
EP1338595B1
(en)
|
2002-02-25 |
2006-05-03 |
Eisai Co., Ltd. |
Xanthine derivatives as DPP-IV inhibitors
|
MXPA03000966A
(es)
|
2002-02-28 |
2003-09-04 |
Pfizer Prod Inc |
Agentes antidiabeticos.
|
GB0205165D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205166D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
HUP0200849A2
(hu)
|
2002-03-06 |
2004-08-30 |
Sanofi-Synthelabo |
N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
|
GB0205176D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205175D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205162D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205170D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
KR100945455B1
(ko)
|
2002-03-22 |
2010-03-05 |
깃세이 야쿠힌 고교 가부시키가이샤 |
글루코피라노실옥시벤질 벤젠 유도체의 결정
|
JP4419571B2
(ja)
|
2002-03-26 |
2010-02-24 |
萬有製薬株式会社 |
新規アミノベンズアミド誘導体
|
JP4298212B2
(ja)
|
2002-03-29 |
2009-07-15 |
大日本印刷株式会社 |
塩酸エピナスチン高融点型結晶の製造法
|
JP2003300977A
(ja)
|
2002-04-10 |
2003-10-21 |
Sumitomo Pharmaceut Co Ltd |
キサンチン誘導体
|
DE10215908B4
(de)
|
2002-04-11 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
|
IL164249A0
(en)
|
2002-04-11 |
2005-12-18 |
Aventis Pharma Gmbh |
Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
|
US6683106B2
(en)
|
2002-04-15 |
2004-01-27 |
Pfizer Inc. |
N-(indole-2-carbonyl)-b-alaninamide crystal forms
|
CA2480325A1
(en)
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Solid forms of salts with tyrosine kinase activity
|
WO2003091213A1
(fr)
|
2002-04-25 |
2003-11-06 |
Yamanouchi Pharmaceutical Co., Ltd. |
Derives d'amide ou sels de ces derives
|
ES2276097T3
(es)
|
2002-04-26 |
2007-06-16 |
F. Hoffmann-La Roche Ag |
Fenilacetamidas sustituidas y su empleo0 como activadores de glucoquinasa.
|
CA2484306A1
(en)
|
2002-04-26 |
2003-11-06 |
Katsumi Maezono |
Prophylactic and therapeutic agent of diabetes mellitus
|
AU2003231252A1
(en)
|
2002-05-09 |
2003-11-11 |
Enos Pharmaceuticals, Inc. |
Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
|
GB2388594A
(en)
*
|
2002-05-16 |
2003-11-19 |
Bayer Ag |
Imidazo-triazine PDE 4 inhibitors
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
GB0212412D0
(en)
*
|
2002-05-29 |
2002-07-10 |
Novartis Ag |
Combination of organic compounds
|
CN101538224A
(zh)
|
2002-05-31 |
2009-09-23 |
先灵公司 |
制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
|
KR100985160B1
(ko)
|
2002-06-06 |
2010-10-05 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
신규한 축합된 이미다졸 유도체
|
DE10225635C1
(de)
|
2002-06-07 |
2003-12-24 |
Aventis Pharma Gmbh |
N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
|
AR040241A1
(es)
|
2002-06-10 |
2005-03-23 |
Merck & Co Inc |
Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
|
ES2199061B1
(es)
|
2002-06-10 |
2005-02-16 |
Laboratorios Vita, S.A. |
Comprimidos bucodispersables y procedimiento para su obtencion.
|
FR2840897B1
(fr)
|
2002-06-14 |
2004-09-10 |
Fournier Lab Sa |
Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
|
EP2471533A1
(en)
|
2002-06-27 |
2012-07-04 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
US20040002615A1
(en)
|
2002-06-28 |
2004-01-01 |
Allen David Robert |
Preparation of chiral amino-nitriles
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
MXPA05000055A
(es)
|
2002-07-11 |
2005-04-08 |
Aventis Pharma Gmbh |
Acilureas sustituidas con urea y uretano, metodos para su produccion y su uso.
|
DE50312261D1
(de)
|
2002-07-12 |
2010-02-04 |
Sanofi Aventis Deutschland |
Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
US20040023981A1
(en)
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Salt forms with tyrosine kinase activity
|
TW200409746A
(en)
|
2002-07-26 |
2004-06-16 |
Theravance Inc |
Crystalline β2 adrenergic receptor agonist
|
BR0312957A
(pt)
|
2002-07-27 |
2005-06-14 |
Astrazeneca Ab |
Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
|
TWI254635B
(en)
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
MXPA05001549A
(es)
|
2002-08-08 |
2005-05-05 |
Kissei Pharmaceutical |
Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
|
CA2478889A1
(en)
|
2002-08-09 |
2004-02-19 |
Taisho Pharmaceutical Co., Ltd. |
Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
|
TW200404796A
(en)
|
2002-08-19 |
2004-04-01 |
Ono Pharmaceutical Co |
Nitrogen-containing compound
|
DE10238243A1
(de)
|
2002-08-21 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
EP2308878A3
(de)
*
|
2002-08-21 |
2011-10-26 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
8-[3-Amino-Piperidin-1-YL] -Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
DE10238477A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10238470A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7495005B2
(en)
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
DE10238724A1
(de)
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
DE10238723A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
JP2004137245A
(ja)
|
2002-08-23 |
2004-05-13 |
Kissei Pharmaceut Co Ltd |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
JP4606876B2
(ja)
|
2002-08-27 |
2011-01-05 |
キッセイ薬品工業株式会社 |
ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
|
EP1537880A4
(en)
|
2002-09-11 |
2009-07-01 |
Takeda Pharmaceutical |
PREPARATION FOR PROLONGED RELEASE
|
BR0314356A
(pt)
|
2002-09-16 |
2005-07-19 |
Wyeth Corp |
Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
|
US7262207B2
(en)
|
2002-09-19 |
2007-08-28 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
NZ538936A
(en)
|
2002-09-26 |
2006-12-22 |
Eisai Co Ltd |
Combination drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide
|
NZ539013A
(en)
|
2002-10-03 |
2007-05-31 |
Novartis Ag |
Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
|
CA2499329C
(en)
|
2002-10-03 |
2009-04-21 |
F. Hoffmann-La Roche Ag |
Indole-3-carboxamides as glucokinase (gk) activators
|
DE10246434B4
(de)
|
2002-10-04 |
2005-08-04 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituierte Acyl-carboxyphenyl-harnstoffderivate und ihre Verwendung als Arzneimittel
|
AU2003269850A1
(en)
|
2002-10-08 |
2004-05-04 |
Novo Nordisk A/S |
Hemisuccinate salts of heterocyclic dpp-iv inhibitors
|
EP1558218A1
(en)
|
2002-10-08 |
2005-08-03 |
Ranbaxy Laboratories Limited |
Gabapentin tablets and methods for their preparation
|
US20040122048A1
(en)
*
|
2002-10-11 |
2004-06-24 |
Wyeth Holdings Corporation |
Stabilized pharmaceutical composition containing basic excipients
|
BR0315166A
(pt)
|
2002-10-11 |
2005-08-16 |
Astrazeneca Ab |
Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
|
US6861526B2
(en)
|
2002-10-16 |
2005-03-01 |
Pfizer Inc. |
Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
|
DE60320008T2
(de)
|
2002-10-18 |
2009-06-18 |
Merck & Co., Inc. |
Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
|
JP2004161749A
(ja)
|
2002-10-24 |
2004-06-10 |
Toray Fine Chemicals Co Ltd |
光学活性含窒素化合物の製造方法
|
EP1556040A1
(en)
|
2002-10-24 |
2005-07-27 |
Sterix Limited |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
|
JP2006507359A
(ja)
|
2002-10-28 |
2006-03-02 |
ノボ・ノルデイスク・エー/エス |
心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
|
AU2003280680A1
(en)
|
2002-11-01 |
2004-06-18 |
Sumitomo Pharmaceuticals Co., Ltd. |
Xanthine compound
|
JP4413863B2
(ja)
|
2002-11-07 |
2010-02-10 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
|
BR0316099A
(pt)
|
2002-11-07 |
2005-09-27 |
Pfizer Prod Inc |
Agentes antidiabéticos
|
AU2003276458A1
(en)
|
2002-11-07 |
2004-06-07 |
Astrazeneca Ab |
2-oxo-ethanesulfonamide derivates
|
DE10251927A1
(de)
|
2002-11-08 |
2004-05-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7482337B2
(en)
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10254304A1
(de)
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7109192B2
(en)
*
|
2002-12-03 |
2006-09-19 |
Boehringer Ingelheim Pharma Gmbh & Co Kg |
Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
|
UY28103A1
(es)
*
|
2002-12-03 |
2004-06-30 |
Boehringer Ingelheim Pharma |
Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
|
JP4651934B2
(ja)
|
2002-12-04 |
2011-03-16 |
キッセイ薬品工業株式会社 |
ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
|
CA2505771A1
(en)
|
2002-12-10 |
2004-06-24 |
Novartis Ag |
Combination of an dpp-iv inhibitor and a ppar-alpha compound
|
PE20040801A1
(es)
|
2002-12-12 |
2004-11-25 |
Hoffmann La Roche |
Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
|
DE10258008B4
(de)
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
JP2004196702A
(ja)
|
2002-12-18 |
2004-07-15 |
Yamanouchi Pharmaceut Co Ltd |
新規なアミド誘導体又はその塩
|
DE10351663A1
(de)
|
2002-12-20 |
2004-07-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
|
JO2397B1
(en)
|
2002-12-20 |
2007-06-17 |
ميرك شارب اند دوم كوربوريشن |
Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
|
US20040152720A1
(en)
|
2002-12-20 |
2004-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
|
WO2004056744A1
(en)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
|
AU2003289440A1
(en)
|
2002-12-25 |
2004-07-22 |
Kissei Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
|
CA2509086C
(en)
|
2003-01-06 |
2012-08-21 |
Eli Lilly And Company |
Substituted arylcyclopropylacetamides as glucokinase activators
|
AU2003294376A1
(en)
|
2003-01-06 |
2004-08-10 |
Eli Lilly And Company |
Heteroaryl compounds
|
SI1599222T1
(sl)
|
2003-01-08 |
2009-08-31 |
Novartis Vaccines & Diagnostic |
Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
|
NZ540612A
(en)
|
2003-01-14 |
2008-02-29 |
Arena Pharm Inc |
1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
DE10335027A1
(de)
*
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
DE10302452B4
(de)
|
2003-01-23 |
2005-02-24 |
Aventis Pharma Deutschland Gmbh |
Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
|
TW200503994A
(en)
|
2003-01-24 |
2005-02-01 |
Novartis Ag |
Organic compounds
|
PL378117A1
(pl)
|
2003-02-11 |
2006-03-06 |
Prosidion Limited |
Tricyklopodstawione związki amidowe
|
EP1594863A1
(en)
|
2003-02-11 |
2005-11-16 |
Prosidion Limited |
Tri(cyclo) substituted amide glucokinase activator compounds
|
MXPA05008619A
(es)
|
2003-02-13 |
2005-11-04 |
Banyu Pharma Co Ltd |
Derivados novedosos de 2-piridincarboxamida.
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
DE10306502B4
(de)
|
2003-02-17 |
2005-03-17 |
Aventis Pharma Deutschland Gmbh |
Substituierte 3-(Benzoylureido)-thiophenderivate und sie enthaltende Arzneimittel
|
JP2004250336A
(ja)
|
2003-02-18 |
2004-09-09 |
Kao Corp |
コーティング錠及び糖衣錠の製造法
|
US7432287B2
(en)
|
2003-02-26 |
2008-10-07 |
Banyu Pharmeceutical Co., Ltd. |
Heteroarylcarbamoylbenzene derivative
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
US7442387B2
(en)
|
2003-03-06 |
2008-10-28 |
Astellas Pharma Inc. |
Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
|
DE10309929B4
(de)
|
2003-03-07 |
2006-02-23 |
Sanofi-Aventis Deutschland Gmbh |
Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
|
MXPA05009564A
(es)
|
2003-03-12 |
2005-11-17 |
Univ Arizona |
Sales de bases debiles.
|
RU2317288C3
(ru)
|
2003-03-14 |
2021-03-10 |
Астеллас Фарма Инк. |
С-гликозидные производные и их соли
|
CA2516142A1
(en)
|
2003-03-18 |
2004-09-30 |
Novartis Ag |
Compositions comprising fatty acids and amino acids
|
JP2004300102A
(ja)
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
JPWO2004089966A1
(ja)
|
2003-04-01 |
2006-07-06 |
大正製薬株式会社 |
選択的なヘテロアリール5−チオ−β−D−アルドヘキソピラノシドの製造法
|
ES2528669T3
(es)
|
2003-04-08 |
2015-02-11 |
Progenics Pharmaceuticals, Inc. |
Formulaciones farmacéuticas que contienen metilnaltrexona
|
EP1615697A2
(en)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
|
ES2338656T3
(es)
|
2003-04-11 |
2010-05-11 |
High Point Pharmaceuticals, Llc |
Uso farmaceutico de 1,2,4-triazoles fusionados.
|
EP1615637A1
(en)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
Pharmaceutical use of substituted 1,2,4-triazoles
|
JP4629657B2
(ja)
|
2003-04-11 |
2011-02-09 |
ハイ・ポイント・ファーマスーティカルズ、エルエルシー |
11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物
|
WO2004092158A1
(en)
|
2003-04-17 |
2004-10-28 |
Pfizer Products Inc. |
Carboxamide derivatives as anti-diabetic agents
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
WO2004096806A1
(ja)
|
2003-04-30 |
2004-11-11 |
Sumitomo Pharmaceuticals Co. Ltd. |
縮合イミダゾール誘導体
|
MXPA05011702A
(es)
|
2003-04-30 |
2006-01-23 |
Pfizer Prod Inc |
Agentes antidiabeticos.
|
AU2003902263A0
(en)
|
2003-05-12 |
2003-05-29 |
Fujisawa Pharmaceutical Co., Ltd. |
Monosaccharide compounds
|
NZ543482A
(en)
|
2003-05-21 |
2009-02-28 |
Prosidion Ltd |
Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
|
EP1631558A1
(en)
|
2003-05-21 |
2006-03-08 |
Biovitrum Ab |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
|
TW200510277A
(en)
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
FR2855521B1
(fr)
|
2003-05-28 |
2005-08-05 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
|
DE602004028473D1
(de)
|
2003-05-29 |
2010-09-16 |
Merck Sharp & Dohme |
Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
|
AU2003902828A0
(en)
|
2003-06-05 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
JP2004359630A
(ja)
|
2003-06-06 |
2004-12-24 |
Yamanouchi Pharmaceut Co Ltd |
ジフルオロジフェニルメタン誘導体及びその塩
|
US7566707B2
(en)
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10327439A1
(de)
|
2003-06-18 |
2005-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
WO2004113345A1
(ja)
|
2003-06-20 |
2004-12-29 |
Japan Tobacco Inc. |
縮合ピロール化合物及びその医薬用途
|
CN101090901B
(zh)
|
2003-06-20 |
2010-12-15 |
霍夫曼-拉罗奇有限公司 |
作为dpp-iv抑制剂的六氢吡啶并异喹啉类
|
CA2529878C
(en)
|
2003-06-20 |
2012-11-20 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, drug composition containing the same and production intermediate therefor
|
EA009591B1
(ru)
*
|
2003-06-20 |
2008-02-28 |
Ф.Хоффманн-Ля Рош Аг |
Производные пиридо[2,1-а]изохинолина в качестве ингибиторов dpp-iv
|
JO2625B1
(en)
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
WO2004113310A1
(en)
|
2003-06-25 |
2004-12-29 |
Biovitrum Ab |
Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
|
US7364755B2
(en)
|
2003-07-07 |
2008-04-29 |
Synthon Ip Inc. |
Modified calcium phosphate excipient
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
TWI335328B
(en)
|
2003-07-14 |
2011-01-01 |
Arena Pharm Inc |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
|
US20050027012A1
(en)
|
2003-07-16 |
2005-02-03 |
Boehringer Ingelheim International Gmbh |
Tablets containing ambroxol
|
ATE457166T1
(de)
|
2003-07-24 |
2010-02-15 |
Wockhardt Ltd |
Orale zusammensetzungen zur behandlung von diabetes
|
BRPI0413234A
(pt)
|
2003-08-01 |
2006-10-03 |
Genelabs Tech Inc |
derivados de imidazola bicìclica contra flaviviridae
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
EP1651658B2
(en)
|
2003-08-01 |
2020-08-12 |
Mitsubishi Tanabe Pharma Corporation |
Novel compounds having inhibitory activity against sodium-dependant transporter
|
EA010422B1
(ru)
|
2003-08-01 |
2008-08-29 |
Янссен Фармацевтика Н.В. |
Замещённые индол-о-глюкозиды
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
EP1679965A4
(en)
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
|
EP1679966A4
(en)
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
BENZIMIDAZOLE-, BENZTRIAZOLE- AND BENZIMIDAZOLONE-SUBSTITUTED O-GLUCOSIDES
|
EP1680414A4
(en)
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
SUBSTITUTED INDAZOLE-O-GLUCOSIDE
|
JP2007501789A
(ja)
|
2003-08-07 |
2007-02-01 |
メルク エンド カムパニー インコーポレーテッド |
11−β−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのピラゾールカルボキサミド
|
GB0318464D0
(en)
|
2003-08-07 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
GB0318463D0
(en)
|
2003-08-07 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
KR101293503B1
(ko)
|
2003-08-14 |
2013-08-07 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 vii 폴리펩티드의 액상 수성 약학적 조성물
|
GB0319690D0
(en)
|
2003-08-22 |
2003-09-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0319759D0
(en)
|
2003-08-22 |
2003-09-24 |
Astrazeneca Ab |
Chemical compounds
|
CA2539032A1
(en)
|
2003-08-26 |
2005-03-10 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
|
WO2005020986A1
(en)
|
2003-08-29 |
2005-03-10 |
Astrazeneca Ab |
Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
|
AU2004270150C1
(en)
|
2003-08-29 |
2011-07-14 |
Merck Hdac Research, Llc |
Combination methods of treating cancer
|
WO2005020985A1
(en)
|
2003-08-29 |
2005-03-10 |
Astrazeneca Ab |
Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
|
GB0320422D0
(en)
|
2003-08-30 |
2003-10-01 |
Astrazeneca Ab |
Chemical compounds
|
US7790734B2
(en)
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
ATE534404T1
(de)
|
2003-10-03 |
2011-12-15 |
Takeda Pharmaceutical |
Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe
|
US7284625B2
(en)
|
2003-10-22 |
2007-10-23 |
Kirk Jones |
Quick connect assembly for ATV implements
|
CA2540843A1
(en)
|
2003-10-23 |
2005-05-12 |
Sterix Limited |
Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
|
US20050091394A1
(en)
|
2003-10-27 |
2005-04-28 |
Schneider Automation Inc. |
Software configurable dual cable redundant Ethernet or bus configuration
|
US7246174B2
(en)
|
2003-10-28 |
2007-07-17 |
Nacon Consulting, Llc |
Method and system for accessing and managing virtual machines
|
BR0304443B1
(pt)
|
2003-10-28 |
2012-08-21 |
|
processo para obtenção de concentrados de titánio com elevado teor de tio2 e baixo teor de radionuclìdeos a partir de concentrados mecánicos de anatásio.
|
AU2004286836A1
(en)
|
2003-10-28 |
2005-05-19 |
Amgen Inc. |
Triazole compounds and uses related thereto
|
GB0325402D0
(en)
|
2003-10-31 |
2003-12-03 |
Astrazeneca Ab |
Compounds
|
GB0325745D0
(en)
|
2003-11-05 |
2003-12-10 |
Astrazeneca Ab |
Chemical compounds
|
GB0326029D0
(en)
|
2003-11-07 |
2003-12-10 |
Astrazeneca Ab |
Chemical compounds
|
US7107714B2
(en)
|
2003-11-10 |
2006-09-19 |
Marketing Displays, Inc. |
Portable snap-fit sign stand
|
KR20060109911A
(ko)
*
|
2003-11-17 |
2006-10-23 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
JP2005170939A
(ja)
|
2003-11-20 |
2005-06-30 |
Takeda Chem Ind Ltd |
糖尿病の予防・治療剤
|
EP1532980A1
(en)
|
2003-11-24 |
2005-05-25 |
Novo Nordisk A/S |
N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
|
DE10355304A1
(de)
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
GB0327760D0
(en)
|
2003-11-29 |
2003-12-31 |
Astrazeneca Ab |
Compounds
|
GB0327761D0
(en)
|
2003-11-29 |
2003-12-31 |
Astrazeneca Ab |
Compounds
|
WO2005053695A1
(ja)
|
2003-12-04 |
2005-06-16 |
Eisai Co., Ltd. |
多発性硬化症予防剤または治療剤
|
GB0328178D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Compounds
|
DE10359098A1
(de)
|
2003-12-17 |
2005-07-28 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
|
US7217711B2
(en)
|
2003-12-17 |
2007-05-15 |
Boehringer Ingelheim International Gmbh |
Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
|
ATE501135T1
(de)
|
2003-12-18 |
2011-03-15 |
Tibotec Pharm Ltd |
Piperidinamino-benzimidazol-derivate al respiratorisches syncytialvirus replikation inhibitoren
|
EA200600990A1
(ru)
|
2003-12-19 |
2006-10-27 |
Пфайзер Инк. |
Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
|
DE10361133A1
(de)
|
2003-12-22 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
EP1703908A4
(en)
|
2003-12-22 |
2009-07-08 |
Amgen Inc |
ARYLSULFONAMIDE COMPOUNDS AND RELATED APPLICATIONS
|
DE10360835A1
(de)
|
2003-12-23 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
|
CA2549955A1
(en)
|
2003-12-24 |
2005-07-07 |
Prosidion Limited |
Heterocyclic derivatives as gpcr receptor agonists
|
AU2004309287B2
(en)
|
2003-12-29 |
2008-07-31 |
Banyu Pharmaceutical Co., Ltd |
Novel 2-heteroaryl-substituted benzimidazole derivative
|
JP2007517800A
(ja)
|
2004-01-06 |
2007-07-05 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
糖尿病および肥満を処置するためのグリコーゲンホスホリラーゼインヒビターとしての(3−オキソ−3,4−ジヒドロ−キノキサリン−2−イル−アミノ)−ベンズアミド誘導体および関連化合物
|
PL1723128T3
(pl)
|
2004-01-06 |
2013-04-30 |
Novo Nordisk As |
Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
|
WO2005070390A2
(en)
|
2004-01-21 |
2005-08-04 |
Janssen Pharmaceutica N.V. |
Mitratapide oral solution
|
IN2012DN03023A
(pt)
|
2004-01-26 |
2015-07-31 |
Merck Sharp & Dohme |
|
DE102004004972B3
(de)
|
2004-01-31 |
2005-09-15 |
Aventis Pharma Deutschland Gmbh |
Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2005073229A1
(de)
|
2004-01-31 |
2005-08-11 |
Sanofi-Aventis Deutschland Gmbh |
7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
DE102004004971B3
(de)
|
2004-01-31 |
2005-09-15 |
Aventis Pharma Deutschland Gmbh |
Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
|
US20050239853A1
(en)
|
2004-02-04 |
2005-10-27 |
Tjeerd Barf |
New compounds
|
JP2005247834A
(ja)
|
2004-02-04 |
2005-09-15 |
Taisho Pharmaceut Co Ltd |
ナトリウム依存性グルコース供輸送体2の活性阻害剤
|
SE0400234D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New compounds, methods for their preparation and use thereof
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
EP1718625A1
(en)
|
2004-02-18 |
2006-11-08 |
AstraZeneca AB |
Compounds
|
EP1758905B1
(de)
*
|
2004-02-18 |
2009-04-29 |
Boehringer Ingelheim International GmbH |
8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
|
EP2048137A1
(en)
|
2004-02-18 |
2009-04-15 |
AstraZeneca AB |
Benzamide derivatives and their use as glucokinase activating agents.
|
DE102004019540A1
(de)
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
|
DE102004009039A1
(de)
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
US7732596B2
(en)
|
2004-03-04 |
2010-06-08 |
Kissei Pharmaceutical Co., Ltd. |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
EP1724278B1
(en)
|
2004-03-04 |
2014-05-07 |
Kissei Pharmaceutical Co., Ltd. |
Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
|
JP4950657B2
(ja)
|
2004-03-04 |
2012-06-13 |
キッセイ薬品工業株式会社 |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
EP1725555B1
(en)
|
2004-03-08 |
2010-10-06 |
Prosidion Ltd. |
Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
|
WO2005085194A2
(en)
|
2004-03-08 |
2005-09-15 |
Prosidion Limited |
Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
CN102134230B
(zh)
|
2004-03-15 |
2019-06-28 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
EA011158B1
(ru)
|
2004-03-16 |
2009-02-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
EP1577306A1
(de)
|
2004-03-17 |
2005-09-21 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
|
CA2560286A1
(en)
|
2004-03-23 |
2005-09-29 |
Banyu Pharmaceutical Co., Ltd. |
Substituted quinazoline or pyridopyrimidine derivative
|
US7354938B2
(en)
|
2004-03-23 |
2008-04-08 |
Amgen Inc. |
Pyrazole compounds and uses related thereto
|
JP2007530690A
(ja)
|
2004-03-29 |
2007-11-01 |
メルク エンド カムパニー インコーポレーテッド |
11−β−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのジアリールトリアゾール
|
TW200602335A
(en)
|
2004-03-31 |
2006-01-16 |
Kissei Pharmaceutical |
Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
|
EP1731524A4
(en)
|
2004-03-31 |
2009-05-20 |
Kissei Pharmaceutical |
PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
|
WO2005095372A1
(ja)
|
2004-03-31 |
2005-10-13 |
Kissei Pharmaceutical Co., Ltd. |
ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
|
JP2007530631A
(ja)
|
2004-04-02 |
2007-11-01 |
ノバルティス アクチエンゲゼルシャフト |
チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
|
EP1735322B1
(en)
|
2004-04-02 |
2011-09-14 |
Novartis AG |
Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes
|
JP2007261945A
(ja)
|
2004-04-07 |
2007-10-11 |
Taisho Pharmaceut Co Ltd |
チアゾール誘導体
|
JP2007531780A
(ja)
|
2004-04-10 |
2007-11-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規な2−アミノ−イミダゾ[4,5−d]ピリダジン−4−オン及び2−アミノ−イミダゾ[4,5−c]ピリダジン−4−オン、その製法及び医薬としての使用
|
US7179809B2
(en)
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
EP1735275B1
(en)
|
2004-04-14 |
2010-08-18 |
Amgen Inc. |
Aryl sulfones and uses related thereto
|
GB0408771D0
(en)
|
2004-04-20 |
2004-05-26 |
Sterix Ltd |
Compound
|
WO2005118538A2
(en)
|
2004-04-20 |
2005-12-15 |
Amgen, Inc. |
Arylsulfonamides and uses as hydroxysteroid dehydrogenase
|
US20080242869A1
(en)
|
2004-04-21 |
2008-10-02 |
Matthew Fyfe |
Tri(Cyclo) Substituted Amide Compounds
|
US20050239778A1
(en)
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim International Gmbh |
Novel medicament combinations for the treatment of respiratory diseases
|
US20050244502A1
(en)
|
2004-04-28 |
2005-11-03 |
Mathias Neil R |
Composition for enhancing absorption of a drug and method
|
US20050245533A1
(en)
|
2004-04-29 |
2005-11-03 |
Hoff Ethan D |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application
|
US20050245534A1
(en)
|
2004-04-29 |
2005-11-03 |
Link James T |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
|
US20050245532A1
(en)
|
2004-04-29 |
2005-11-03 |
Hoff Ethan D |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
|
US7880001B2
(en)
|
2004-04-29 |
2011-02-01 |
Abbott Laboratories |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
|
US20050261302A1
(en)
|
2004-04-29 |
2005-11-24 |
Hoff Ethan D |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
|
WO2005107730A2
(en)
*
|
2004-05-03 |
2005-11-17 |
Omega Bio-Pharma (I.P.3) Limited |
Cysteamines for treating complications of hypercholesterolemia and diabetes
|
CA2565843A1
(en)
|
2004-05-06 |
2005-11-17 |
Pfizer Inc. |
Novel compounds of proline and morpholine derivatives
|
NZ551077A
(en)
|
2004-05-07 |
2009-05-31 |
Janssen Pharmaceutica Nv |
Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
|
TWI350168B
(en)
|
2004-05-07 |
2011-10-11 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals
|
NZ551076A
(en)
|
2004-05-07 |
2009-05-31 |
Janssen Pharmaceutica Nv |
Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
|
US7439370B2
(en)
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
AU2005247684B2
(en)
|
2004-05-12 |
2008-10-23 |
Pfizer Products Inc. |
Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
|
DE102004024454A1
(de)
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
BRPI0510394A
(pt)
|
2004-05-24 |
2007-11-13 |
Amgen Inc |
inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
|
TWI354569B
(en)
|
2004-05-28 |
2011-12-21 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
ZA200610041B
(en)
|
2004-06-01 |
2008-07-30 |
Ares Trading Sa |
Method of stabilizing proteins
|
CA2569095A1
(en)
|
2004-06-03 |
2005-12-15 |
Pfizer Products Inc. |
Crystal structure of dipeptidyl peptidase iv (dpp-iv) and uses thereof
|
US7935723B2
(en)
|
2004-06-04 |
2011-05-03 |
Novartis Pharma Ag |
Use of organic compounds
|
TW200600086A
(en)
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
EP1604989A1
(en)
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
DPP-IV inhibitors
|
EP1753459A2
(en)
|
2004-06-09 |
2007-02-21 |
Yasoo Health |
Composition and method for improving pancreatic islet cell survival
|
DE102004028241B4
(de)
|
2004-06-11 |
2007-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
|
US8071624B2
(en)
|
2004-06-24 |
2011-12-06 |
Incyte Corporation |
N-substituted piperidines and their use as pharmaceuticals
|
US20050288317A1
(en)
|
2004-06-24 |
2005-12-29 |
Wenqing Yao |
Amido compounds and their use as pharmaceuticals
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
EA200700118A1
(ru)
|
2004-06-24 |
2007-08-31 |
Инсайт Корпорейшн |
Амидосоединения и их применение в качестве лекарственных средств
|
JP2008504276A
(ja)
|
2004-06-24 |
2008-02-14 |
インサイト・コーポレイション |
アミド化合物およびその医薬としての使用
|
EP1773773A4
(en)
|
2004-06-24 |
2009-07-29 |
Incyte Corp |
AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
|
EP1763517B1
(en)
|
2004-06-28 |
2011-05-11 |
F. Hoffmann-La Roche AG |
Pyrimidine derivatives as 11beta-hsd1 inhibitors
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
CA2511269A1
(en)
*
|
2004-07-07 |
2006-01-07 |
F. Hoffmann-La Roche Ag |
Multimarker panel based on p1gf for diabetes type 1 and 2
|
CN101018550A
(zh)
|
2004-07-14 |
2007-08-15 |
诺瓦提斯公司 |
Dpp-iv抑制剂与调节5-ht3和/或5-ht4受体的化合物的组合
|
DE102004034690A1
(de)
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
JP2008508213A
(ja)
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
|
SI1789041T1
(sl)
|
2004-07-28 |
2008-10-31 |
Hoffmann La Roche |
Derivati aril-piridina kot inhibitorji 11-beta-hsd1
|
US20060025445A1
(en)
|
2004-08-02 |
2006-02-02 |
Xiang Jason S |
11-Beta HSD1 inhibitors
|
JP2008509146A
(ja)
|
2004-08-06 |
2008-03-27 |
メルク エンド カムパニー インコーポレーテッド |
11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのスルホニル化合物
|
JP2006045156A
(ja)
|
2004-08-06 |
2006-02-16 |
Sumitomo Pharmaceut Co Ltd |
縮合ピラゾール誘導体
|
CN101080226A
(zh)
|
2004-08-10 |
2007-11-28 |
因塞特公司 |
酰氨基化合物及它们作为药物的用途
|
WO2006018150A1
(de)
|
2004-08-11 |
2006-02-23 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
GB0418046D0
(en)
|
2004-08-12 |
2004-09-15 |
Prosidion Ltd |
Eantioselective process
|
GB0418058D0
(en)
|
2004-08-12 |
2004-09-15 |
Prosidion Ltd |
Fluorination process
|
MX2007001650A
(es)
|
2004-08-12 |
2007-07-13 |
Prosidion Ltd |
Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
|
TW200613275A
(en)
|
2004-08-24 |
2006-05-01 |
Recordati Ireland Ltd |
Lercanidipine salts
|
EP1782832A4
(en)
|
2004-08-26 |
2009-08-26 |
Takeda Pharmaceutical |
MEANS FOR THE TREATMENT OF DIABETES
|
CA2576839C
(en)
|
2004-08-30 |
2013-07-02 |
Janssen Pharmaceutica N.V. |
N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
|
ATE445600T1
(de)
|
2004-08-30 |
2009-10-15 |
Janssen Pharmaceutica Nv |
Derivate von tricyclischem lactam als 11-beta- hydroxysteroid-dehydrogenase-inhibitoren
|
DE102004043944A1
(de)
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CN101014578B
(zh)
|
2004-09-16 |
2011-01-19 |
安斯泰来制药有限公司 |
三唑衍生物或其盐
|
JP4671648B2
(ja)
|
2004-09-17 |
2011-04-20 |
株式会社ソニー・コンピュータエンタテインメント |
中継器、エンタテインメント装置、通信システム、通信方法、及びプログラム
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
CA2580461A1
(en)
|
2004-09-23 |
2006-04-06 |
Amgen Inc. |
Substituted sulfonamidopropionamides and methods of use
|
MX2007003785A
(es)
|
2004-09-29 |
2007-07-12 |
Kissei Pharmaceutical |
Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
RU2383533C2
(ru)
|
2004-10-04 |
2010-03-10 |
Ф.Хоффманн-Ля Рош Аг |
Алкилированные производные пиридина в качестве ингибиторов 11-бета при диабете
|
MX2007004021A
(es)
|
2004-10-08 |
2007-05-24 |
Novartis Ag |
Combinacion de compuestos organicos.
|
JP4959569B2
(ja)
|
2004-10-12 |
2012-06-27 |
グレンマーク・ファーマシューティカルズ・エスエー |
新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス
|
WO2006040329A1
(en)
|
2004-10-12 |
2006-04-20 |
Novo Nordisk A/S |
1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
|
GB0423044D0
(en)
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
GB0423043D0
(en)
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
RU2007119320A
(ru)
|
2004-10-25 |
2008-11-27 |
Новартис АГ (CH) |
Комбинация ингибитора dpp-iv, антидиабетического агента ppar и метформина
|
ATE419848T1
(de)
|
2004-10-29 |
2009-01-15 |
Lilly Co Eli |
Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
|
EP1812407A2
(en)
|
2004-11-02 |
2007-08-01 |
Pfizer, Inc. |
Novel compounds of substituted and unsubstituted adamantyl amides
|
AU2005301608B2
(en)
|
2004-11-02 |
2012-09-13 |
Msd K.K. |
Aryloxy-substituted benzimidazole derivatives
|
DE102005013967A1
(de)
|
2004-11-05 |
2006-10-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1655283A1
(en)
|
2004-11-08 |
2006-05-10 |
Evotec OAI AG |
11beta-HSD1 Inhibitors
|
EP1666467A1
(en)
|
2004-11-08 |
2006-06-07 |
Evotec AG |
11Beta-HSD1 Inhibitors
|
EP1659113A1
(en)
|
2004-11-08 |
2006-05-24 |
Evotec AG |
Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
|
WO2006051662A1
(ja)
|
2004-11-09 |
2006-05-18 |
Taisho Pharmaceutical Co., Ltd. |
チアゾール誘導体
|
BRPI0517567A
(pt)
|
2004-11-09 |
2008-06-17 |
Smithkline Beecham Corp |
composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−2組成物
|
MX2007005527A
(es)
|
2004-11-10 |
2007-07-09 |
Incyte Corp |
Compuestos de lactama y sus usos como farmaceuticos.
|
US7365061B2
(en)
|
2004-11-15 |
2008-04-29 |
Bristol-Myers Squibb Company |
2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
|
WO2006055435A1
(en)
|
2004-11-15 |
2006-05-26 |
Bristol-Myers Squibb Company |
2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
|
US7214704B2
(en)
|
2004-11-15 |
2007-05-08 |
Bristol-Myers Squibb Company |
2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
|
WO2006055462A1
(en)
|
2004-11-15 |
2006-05-26 |
Bristol-Myers Squibb Company |
2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
|
US7750145B2
(en)
|
2004-11-18 |
2010-07-06 |
Kissei Pharmaceutical Co., Ltd. |
1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
|
EP1824842A4
(en)
|
2004-11-18 |
2009-08-26 |
Incyte Corp |
INHIBITORS OF 11-HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHOD OF USE
|
GB0425919D0
(en)
|
2004-11-25 |
2004-12-29 |
Prosidion Ltd |
Indole-2-carboxylic acid amides
|
WO2006059163A1
(en)
|
2004-12-02 |
2006-06-08 |
Prosidion Limited |
Treatment of diabetes with glycogen phosphorylase inhibitors
|
WO2006059165A1
(en)
|
2004-12-02 |
2006-06-08 |
Prosidion Limited |
Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
|
JP2008521873A
(ja)
|
2004-12-02 |
2008-06-26 |
プロシディオン・リミテッド |
ピロロピリジン−2−カルボン酸アミド類
|
MX2007006420A
(es)
|
2004-12-03 |
2007-07-19 |
Novo Nordisk As |
Activadores heteroaromaticos de glucocinasa.
|
JP2008007405A
(ja)
|
2004-12-07 |
2008-01-17 |
Takeda Chem Ind Ltd |
カルボキサミド誘導体
|
US7687469B2
(en)
|
2004-12-16 |
2010-03-30 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2008524244A
(ja)
|
2004-12-17 |
2008-07-10 |
タケダ サン ディエゴ インコーポレイテッド |
水酸化ステロイド脱水素酵素阻害剤
|
DK1830841T3
(da)
|
2004-12-20 |
2008-10-13 |
Lilly Co Eli |
Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
|
WO2006068991A1
(en)
|
2004-12-21 |
2006-06-29 |
Eli Lilly And Company |
Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
|
WO2006068199A1
(ja)
|
2004-12-22 |
2006-06-29 |
Mochida Pharmaceutical Co., Ltd. |
代謝的に安定な3-オキシ-1,2,4-トリアゾール誘導体
|
AU2005320134B2
(en)
|
2004-12-24 |
2011-04-28 |
Dainippon Sumitomo Pharma Co., Ltd. |
Bicyclic pyrrole derivatives
|
KR100760430B1
(ko)
|
2004-12-31 |
2007-10-04 |
한미약품 주식회사 |
당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
|
WO2006074244A2
(en)
|
2005-01-05 |
2006-07-13 |
Abbott Laboratories |
Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
|
US20060148871A1
(en)
|
2005-01-05 |
2006-07-06 |
Rohde Jeffrey J |
Metabolic stabilization of substituted adamantane
|
JP5133702B2
(ja)
|
2005-01-05 |
2013-01-30 |
アボット・ラボラトリーズ |
11−β−ヒドロキシステロイドデヒドロゲナーゼ1型酵素の阻害薬
|
TW200637839A
(en)
|
2005-01-07 |
2006-11-01 |
Taisho Pharmaceutical Co Ltd |
1-thio-d-glucitol derivatives
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
GT200600008A
(es)
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
WO2006080533A1
(ja)
|
2005-01-31 |
2006-08-03 |
Mochida Pharmaceutical Co., Ltd. |
3-アミノ-1,2,4-トリアゾール誘導体
|
AR053329A1
(es)
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
EP1848693A1
(en)
|
2005-02-05 |
2007-10-31 |
AstraZeneca AB |
Indan-amide derivatives with glycogen phosphorylase inhibitory activity
|
US20100137397A1
(en)
|
2005-02-05 |
2010-06-03 |
Astrazeneca Ab |
Chemical Compounds
|
JP5020065B2
(ja)
|
2005-02-15 |
2012-09-05 |
キッセイ薬品工業株式会社 |
1−置換−7−(β−D−グリコピラノシルオキシ)(アザ)インドール化合物、及びそれを含有する医薬
|
CA2598610C
(en)
|
2005-03-03 |
2011-05-31 |
F. Hoffmann-La Roche Ag |
1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
|
WO2006095822A1
(ja)
|
2005-03-11 |
2006-09-14 |
Ono Pharmaceutical Co., Ltd. |
スルホンアミド化合物およびその医薬
|
EP1868685A2
(en)
|
2005-03-18 |
2007-12-26 |
onepharm GmbH |
11ß-HYDROXYSTEROID DEHYDROGENASES
|
GB0506133D0
(en)
|
2005-03-24 |
2005-05-04 |
Sterix Ltd |
Compound
|
JPWO2006104280A1
(ja)
|
2005-03-31 |
2008-09-11 |
武田薬品工業株式会社 |
糖尿病の予防・治療剤
|
JP5140577B2
(ja)
|
2005-03-31 |
2013-02-06 |
タケダ カリフォルニア インコーポレイテッド |
ヒドロキシステロイドデヒドロゲナーゼ阻害剤
|
BRPI0610459A2
(pt)
|
2005-04-05 |
2010-06-22 |
Hoffmann La Roche |
composto, processo para a sua preparação, composições farmacêuticas que o compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróides-11b e utilização do composto
|
WO2006106423A2
(en)
|
2005-04-07 |
2006-10-12 |
Pfizer Inc. |
Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
ES2338041T3
(es)
|
2005-04-15 |
2010-05-03 |
Boehringer Ingelheim International Gmbh |
Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt.
|
EP1873144B1
(en)
|
2005-04-20 |
2014-07-23 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
WO2006111169A1
(en)
|
2005-04-21 |
2006-10-26 |
Gastrotech Pharma A/S |
Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
|
AP2007004234A0
(en)
|
2005-04-22 |
2007-12-31 |
Alantos Pharm Holding |
Dipeptidyl peptidase-IV inhibitors
|
JP4749417B2
(ja)
|
2005-04-25 |
2011-08-17 |
株式会社日立製作所 |
磁気共鳴を用いた検査装置および核磁気共鳴信号受信用コイル
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
AU2006250354A1
(en)
|
2005-05-23 |
2006-11-30 |
Japan Tobacco Inc. |
Pyrazole compound and therapeutic agent for diabetes comprising the same
|
JP2008542247A
(ja)
|
2005-05-24 |
2008-11-27 |
アストラゼネカ アクチボラグ |
グルコキナーゼモジュレーターとしての2−フェニル置換イミダゾール[4,5b]ピリジン/ピラジンおよびプリン誘導体
|
RU2007143161A
(ru)
|
2005-05-25 |
2009-07-10 |
Вайет (Us) |
Способы синтеза замещенных 3-цианохинов и их продуктов
|
TW200714597A
(en)
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
CN101237870B
(zh)
|
2005-06-03 |
2011-05-25 |
田边三菱制药株式会社 |
伴随的药物试剂及其用途
|
US8952176B2
(en)
|
2005-06-07 |
2015-02-10 |
Shionogi & Co., Ltd. |
Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
|
WO2006132436A1
(ja)
|
2005-06-08 |
2006-12-14 |
Japan Tobacco Inc. |
複素環化合物
|
US7572807B2
(en)
|
2005-06-09 |
2009-08-11 |
Bristol-Myers Squibb Company |
Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
|
US7579360B2
(en)
|
2005-06-09 |
2009-08-25 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
GT200600218A
(es)
|
2005-06-10 |
2007-03-28 |
|
Formulación y proceso de compresión directa
|
WO2006134481A1
(en)
|
2005-06-16 |
2006-12-21 |
Pfizer Inc. |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
|
EP1893609B1
(en)
|
2005-06-16 |
2009-11-18 |
Pfizer, Inc. |
N-(pyridin-2-yl)-sulfonamide derivatives
|
US7605289B2
(en)
|
2005-06-17 |
2009-10-20 |
Amgen, Inc. |
Benzamide derivatives and uses related thereto
|
US7585630B2
(en)
|
2005-06-20 |
2009-09-08 |
Decode Genetics Ehf. |
Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
|
CN101212966B
(zh)
|
2005-07-01 |
2012-03-14 |
默沙东公司 |
合成cetp抑制剂的方法
|
NZ564260A
(en)
|
2005-07-05 |
2010-12-24 |
Hoffmann La Roche |
Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
|
PE20070374A1
(es)
|
2005-07-08 |
2007-05-12 |
Pfizer Ltd |
ANTICUERPOS ANTI-MAdCAM
|
US7999114B2
(en)
|
2005-07-08 |
2011-08-16 |
Novo Nordisk A/S |
Dicycloalkylcarbamoyl ureas as glucokinase activators
|
WO2007007688A1
(ja)
|
2005-07-08 |
2007-01-18 |
Mochida Pharmaceutical Co., Ltd. |
3,5-ジアミノ-1,2,4-トリアゾール誘導体
|
MX2008000294A
(es)
|
2005-07-08 |
2008-04-04 |
Novo Nordisk As |
Activadores de dicicloalquil urea glucocinasa.
|
EP2305674A1
(en)
|
2005-07-09 |
2011-04-06 |
AstraZeneca AB |
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
|
EP2027113A1
(en)
|
2005-07-09 |
2009-02-25 |
AstraZeneca AB |
Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
|
EP1910350A1
(en)
|
2005-07-09 |
2008-04-16 |
AstraZeneca AB |
2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
|
BRPI0613451A2
(pt)
|
2005-07-11 |
2011-01-11 |
Mitsubishi Tanabe Pharma Corp |
ativador de glicocinase, derivado de oxima, método para a preparação do referido derivado de oxima e uso
|
EP1905769B1
(en)
|
2005-07-13 |
2017-03-29 |
Msd K.K. |
Heterocycle-substituted benzimidazole derivative
|
BRPI0612996A2
(pt)
|
2005-07-14 |
2010-12-14 |
Novo Nordisk As |
ativadores de urÉia glucocinase
|
JP2009505955A
(ja)
|
2005-07-22 |
2009-02-12 |
アムゲン インコーポレイティッド |
アニリンスルホンアミド誘導体およびそれらの使用
|
UY29694A1
(es)
|
2005-07-28 |
2007-02-28 |
Boehringer Ingelheim Int |
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20100160286A1
(en)
|
2005-08-09 |
2010-06-24 |
Astrazeneca Uk Limited Ab |
Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
|
AU2006278039B2
(en)
|
2005-08-11 |
2010-10-21 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition comprising a DPP-lV inhibitor
|
US7622492B2
(en)
|
2005-08-31 |
2009-11-24 |
Hoffmann-La Roche Inc. |
Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
|
EP1760076A1
(en)
|
2005-09-02 |
2007-03-07 |
Ferring B.V. |
FAP Inhibitors
|
CA2622472C
(en)
|
2005-09-14 |
2013-11-19 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
GEP20135791B
(en)
|
2005-09-14 |
2013-03-25 |
Takeda Pharmaceutical |
Use of dipeptidyl peptidase inhibitors
|
BRPI0616245A2
(pt)
|
2005-09-16 |
2011-06-14 |
Arena Pharm Inc |
modulador de metabolismo, seus usos, composiÇço farmaceutica compreendendo o mesmo, bem como mÉtodo para produÇço da referida composiÇço
|
ATE514435T1
(de)
|
2005-09-20 |
2011-07-15 |
Novartis Pharma Gmbh |
Verwendung eines dpp-iv-hemmers zur minderung hypoglykämischer ereignisse
|
WO2007038979A1
(en)
|
2005-09-22 |
2007-04-12 |
Swissco Development Ag |
Effervescent metformin composition and tablets and granules made therefrom
|
JOP20180109A1
(ar)
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
BRPI0616640A2
(pt)
|
2005-09-30 |
2011-06-28 |
Novartis Ag |
combinação de compostos orgánicos
|
WO2007050485A2
(en)
|
2005-10-25 |
2007-05-03 |
Merck & Co., Inc. |
Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
|
JP2009515005A
(ja)
|
2005-11-04 |
2009-04-09 |
エルエス ケーブル リミテッド |
水酸化マグネシウムポリマーハイブリッド粒子の製造方法
|
CA2633167A1
(en)
|
2005-12-16 |
2007-07-12 |
Merck & Co., Inc. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
RU2008129873A
(ru)
|
2005-12-23 |
2010-01-27 |
Новартис АГ (CH) |
Конденсированные гетероциклические соединения, полезные в качестве ингибиторов дпп-iv
|
WO2007120936A2
(en)
|
2006-01-06 |
2007-10-25 |
Novartis Ag |
Use.of vildagliptin for the treatment of diabetes
|
TW200801029A
(en)
|
2006-02-15 |
2008-01-01 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
WO2007099345A1
(en)
|
2006-03-02 |
2007-09-07 |
Betagenon Ab |
Medical use of bmp-2 and/ or bmp-4
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
US8455435B2
(en)
|
2006-04-19 |
2013-06-04 |
Ludwig-Maximilians-Universitat Munchen |
Remedies for ischemia
|
CA2810522A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Polymorphs
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
KR20070111099A
(ko)
|
2006-05-16 |
2007-11-21 |
영진약품공업주식회사 |
시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
|
EP2020996B1
(en)
|
2006-05-16 |
2011-11-23 |
Gilead Sciences, Inc. |
Method and compositions for treating hematological malignancies
|
WO2007137107A2
(en)
|
2006-05-19 |
2007-11-29 |
Abbott Laboratories |
Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
|
KR100858848B1
(ko)
|
2006-05-23 |
2008-09-17 |
한올제약주식회사 |
메트포르민 서방정
|
WO2007149797A2
(en)
|
2006-06-19 |
2007-12-27 |
Novartis Ag |
Use of organic compounds
|
WO2007148185A2
(en)
|
2006-06-21 |
2007-12-27 |
Pfizer Products Inc. |
Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
|
AT503443B1
(de)
|
2006-06-23 |
2007-10-15 |
Leopold Franzens Uni Innsbruck |
Verfahren zur herstellung einer eisfläche für eissportbahnen
|
TW200811147A
(en)
|
2006-07-06 |
2008-03-01 |
Arena Pharm Inc |
Modulators of metabolism and the treatment of disorders related thereto
|
TW200811140A
(en)
|
2006-07-06 |
2008-03-01 |
Arena Pharm Inc |
Modulators of metabolism and the treatment of disorders related thereto
|
JP2010500326A
(ja)
|
2006-08-08 |
2010-01-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病の治療のためのdpp−iv阻害剤としてのピロロ[3,2−d]ピリミジン
|
WO2008020011A1
(en)
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
AU2007285827A1
(en)
|
2006-08-17 |
2008-02-21 |
Wellstat Therapeutics Corporation |
Combination treatment for metabolic disorders
|
DE102006042586B4
(de)
|
2006-09-11 |
2014-01-16 |
Betanie B.V. International Trading |
Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten
|
JP2010508371A
(ja)
|
2006-11-06 |
2010-03-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
|
US7956201B2
(en)
|
2006-11-06 |
2011-06-07 |
Hoffman-La Roche Inc. |
Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
|
MY157828A
(en)
|
2006-11-09 |
2016-07-29 |
Boehringer Ingelheim Int |
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
|
US8101634B2
(en)
|
2006-12-06 |
2012-01-24 |
Glaxosmithkline Llc |
Bicyclic compounds and use as antidiabetics
|
ES2319596B1
(es)
|
2006-12-22 |
2010-02-08 |
Laboratorios Almirall S.A. |
Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
AR064736A1
(es)
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr
|
CL2008000133A1
(es)
|
2007-01-19 |
2008-05-23 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
|
CA2677201C
(en)
|
2007-02-01 |
2015-11-17 |
Takeda Pharmaceutical Company Limited |
Solid preparation comprising alogliptin and pioglitazone
|
TW200836774A
(en)
|
2007-02-01 |
2008-09-16 |
Takeda Pharmaceutical |
Solid preparation
|
CA2677457A1
(en)
|
2007-02-06 |
2008-08-14 |
Helen Tuvesson Andersson |
New compounds, methods for their preparation and use thereof
|
JP2010521492A
(ja)
|
2007-03-15 |
2010-06-24 |
ネクティド,インク. |
徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼiv阻害剤組成物を含む抗糖尿病合剤
|
CN103330939A
(zh)
|
2007-04-03 |
2013-10-02 |
田边三菱制药株式会社 |
二肽基肽酶iv抑制化合物和甜味剂的并用
|
EP2142113B1
(en)
|
2007-04-16 |
2023-01-11 |
Smith & Nephew, Inc. |
Powered surgical system
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
JP2010526145A
(ja)
|
2007-05-04 |
2010-07-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
[6,6]および[6,7]−二環式gpr119gタンパク質結合受容体アゴニスト
|
BRPI0721862B1
(pt)
|
2007-07-09 |
2016-03-15 |
Symrise Ag |
preparação compreendendo sais solúveis estáveis de ácido fenilbenzimidazol sulfônico, e uso de aminoácidos básicos
|
KR101536786B1
(ko)
|
2007-07-19 |
2015-07-14 |
다케다 야쿠힌 고교 가부시키가이샤 |
알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
|
PE20090597A1
(es)
|
2007-08-16 |
2009-06-06 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
PE20090603A1
(es)
|
2007-08-16 |
2009-06-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
|
CL2008002424A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
|
NZ600126A
(en)
|
2007-08-17 |
2013-12-20 |
Boehringer Ingelheim Int |
Purine derivatives for use in the treatment of fap-related diseases
|
US8338450B2
(en)
|
2007-09-21 |
2012-12-25 |
Lupin Limited |
Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
|
CN104072613A
(zh)
|
2007-11-13 |
2014-10-01 |
Evec股份有限公司 |
与hGM-CSF结合的单克隆抗体及包含它的药物组合物
|
CN101861333A
(zh)
|
2007-11-16 |
2010-10-13 |
诺沃-诺迪斯克有限公司 |
包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
|
CN101234105A
(zh)
|
2008-01-09 |
2008-08-06 |
北京润德康医药技术有限公司 |
一种含有二甲双胍和维格列汀的药用组合物及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
US20090186086A1
(en)
|
2008-01-17 |
2009-07-23 |
Par Pharmaceutical, Inc. |
Solid multilayer oral dosage forms
|
TW200936136A
(en)
|
2008-01-28 |
2009-09-01 |
Sanofi Aventis |
Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
|
CN101932241A
(zh)
|
2008-02-05 |
2010-12-29 |
默沙东公司 |
二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
|
EP2259676A4
(en)
|
2008-03-04 |
2011-03-16 |
Merck Sharp & Dohme |
PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
|
AU2009220615B2
(en)
|
2008-03-05 |
2013-12-19 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
US20090270404A1
(en)
|
2008-03-31 |
2009-10-29 |
Metabolex, Inc. |
Oxymethylene aryl compounds and uses thereof
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
CN101590007A
(zh)
|
2008-05-27 |
2009-12-02 |
北京瑞伊人科技发展有限公司 |
一种盐酸二甲双胍/伏格列波糖降糖口服制剂组合物及其制备
|
PE20100156A1
(es)
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MX2011001525A
(es)
|
2008-08-15 |
2011-03-29 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
JP2010053576A
(ja)
|
2008-08-27 |
2010-03-11 |
Sumitomo Forestry Co Ltd |
舗装用マット
|
CN102149407A
(zh)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
治疗糖尿病和相关病症的组合疗法
|
UY32177A
(es)
|
2008-10-16 |
2010-05-31 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
|
WO2010045656A2
(en)
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Novel sglt2 inhibitor dosage forms
|
BRPI0923121A2
(pt)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Formas salinas de compostos orgânico
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
DK2395983T3
(da)
|
2009-02-13 |
2020-07-13 |
Boehringer Ingelheim Int |
Farmaceutisk sammensætning omfattende en sglt2-inhibitor, en dpp-iv-inhibitor og eventuelt et yderligere antidiabetisk middel og anvendelser deraf
|
EA029759B1
(ru)
|
2009-02-13 |
2018-05-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
TW201031661A
(en)
|
2009-02-17 |
2010-09-01 |
Targacept Inc |
Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
|
US20120095028A1
(en)
|
2009-03-20 |
2012-04-19 |
Pfizer Inc. |
3-oxa-7-azabicyclo[3.3.1]nonanes
|
BRPI1013992A2
(pt)
|
2009-04-27 |
2016-08-16 |
Revalesio Corp |
composições e métodos para o tratamento de resistência à insulina e diabetes melito
|
US8815292B2
(en)
|
2009-04-27 |
2014-08-26 |
Revalesio Corporation |
Compositions and methods for treating insulin resistance and diabetes mellitus
|
WO2010140111A1
(en)
|
2009-06-02 |
2010-12-09 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
|
AU2010260373A1
(en)
|
2009-06-15 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
|
CN108938585A
(zh)
|
2009-07-21 |
2018-12-07 |
凯克斯生物制药公司 |
柠檬酸铁剂型
|
NZ598170A
(en)
|
2009-10-02 |
2014-06-27 |
Boehringer Ingelheim Int |
Pharmaceutical compositions comprising bi-1356 and metformin
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
JP5446716B2
(ja)
|
2009-10-21 |
2014-03-19 |
大正製薬株式会社 |
アルギニン及びカルニチン含有錠剤の製造方法
|
ES2760917T3
(es)
|
2009-11-27 |
2020-05-18 |
Boehringer Ingelheim Int |
Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
|
JP2010070576A
(ja)
|
2009-12-28 |
2010-04-02 |
Sato Pharmaceutical Co Ltd |
速溶解性錠剤
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
WO2011113947A1
(en)
|
2010-03-18 |
2011-09-22 |
Boehringer Ingelheim International Gmbh |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
KR20130069615A
(ko)
|
2010-05-05 |
2013-06-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
피오글리타존 및 리나글립틴을 포함하는 약제학적 제형
|
JP6034781B2
(ja)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
併用療法
|
JP5707489B2
(ja)
|
2010-06-09 |
2015-04-30 |
ポクセル・エスアーエスPoxelsas |
1型糖尿病の処置
|
AU2011271124A1
(en)
|
2010-06-22 |
2013-01-10 |
Twi Pharmaceuticals, Inc. |
Controlled release compositions with reduced food effect
|
CA3164653A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
A combination comprising linagliptin and a long-acting insulin
|
US20130224296A1
(en)
|
2010-09-03 |
2013-08-29 |
Bristol-Myers Squibb Company |
Drug Formulations Using Water Soluble Antioxidants
|
WO2012039420A1
(ja)
|
2010-09-21 |
2012-03-29 |
国立大学法人九州大学 |
動脈圧反射機能障害に関連した疾患を治療するためのバイオニック動脈圧反射システム
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
WO2012088682A1
(en)
|
2010-12-29 |
2012-07-05 |
Shanghai Fochon Pharmaceutical Co Ltd. |
2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
AU2012212448B9
(en)
|
2011-02-01 |
2015-06-25 |
Astrazeneca Uk Limited |
Pharmaceutical formulations including an amine compound
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
WO2012152837A1
(en)
|
2011-05-10 |
2012-11-15 |
Sandoz Ag |
Polymorph of linagliptin benzoate
|
US8883800B2
(en)
|
2011-07-15 |
2014-11-11 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
CN106968050B
(zh)
|
2012-01-04 |
2019-08-27 |
宝洁公司 |
具有多个区域的含活性物质纤维结构
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171166A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
EP2854812A1
(en)
|
2012-05-24 |
2015-04-08 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2013174769A1
(en)
|
2012-05-25 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
|
WO2013179307A2
(en)
|
2012-05-29 |
2013-12-05 |
Mylan Laboratories Limited |
Stabilized pharmaceutical compositions of saxagliptin
|
NZ704604A
(en)
|
2012-08-24 |
2018-06-29 |
Novartis Ag |
Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
|
EP2908806A1
(en)
|
2012-10-09 |
2015-08-26 |
Boehringer Ingelheim International GmbH |
Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
|
US20140100292A1
(en)
|
2012-10-09 |
2014-04-10 |
Boehringer Ingelheim International Gmbh |
Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets
|
US9050302B2
(en)
|
2013-03-01 |
2015-06-09 |
Jazz Pharmaceuticals Ireland Limited |
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
|
CA2903577C
(en)
|
2013-03-15 |
2023-10-17 |
Boehringer Ingelheim International Gmbh |
Use of linagliptin in cardio- and renoprotective antidiabetic therapy
|
AU2014255727B2
(en)
|
2013-04-18 |
2019-07-25 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2014184376A1
(en)
|
2013-05-17 |
2014-11-20 |
Boehringer Ingelheim International Gmbh |
Combination of a dpp-4 inhibitor and an alpha-glucosidase inhibitor
|
CN105283187A
(zh)
|
2013-06-14 |
2016-01-27 |
勃林格殷格翰国际有限公司 |
用于治疗糖尿病及其并发症的二肽基肽酶-4抑制剂
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
CN104130258B
(zh)
|
2014-08-13 |
2016-06-01 |
广东东阳光药业有限公司 |
一种二聚体的转化方法
|
US20160106677A1
(en)
|
2014-10-17 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
JP2019517542A
(ja)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
リナグリプチンおよびメトホルミンの組合せ
|
WO2020016232A1
(en)
|
2018-07-17 |
2020-01-23 |
Boehringer Ingelheim International Gmbh |
Cardiosafe antidiabetic therapy
|